'Human' insulin firm plans big WSE cash injection

The company is one of the domestic producers of so-called human insulin and has a 7.2% share of the domestic market. Insulin sales constitute 40% of the firm's revenues. Bioton's IPO will see 16 million new shares released on the market. The income will be used to finance the testing of a new medicine, an analogy of human insulin. "We hope we will start the production of the new drug in 6 years," said Bioton management board member Henryk Dąbrowski. In 2003 company revenues totalled zł.107 million, with zł.8 million profit. According to the management board this year results should at least match 2003's figures. Exports play an important role in the company's results, which may amount to zł.35-40 million in 2004. (Parkiet, p. 4) A.F.